IBD at the end of its first century: proceedings of the Falk Symposium 111 held in Freiburg, Germany, 19-20 June, 1999
Although the first description of patients with what we now call Crohn's disease or ulcerative colitis was published well before 1900, both disorders seem to be diseases of the twentieth century. At the very start of the twenty-first century, it therefore seems appropriate to look back and at the same time look forward and to assess what knowledge has been gained during the last 100 years and in what direction research and thereby clinical practice will go in the future. This book, the proceedings of Falk Symposium No. 111 held in Freiburg, Germany, on June 19-20 1999, contains contributions from experienced senior scientists on the state of the art in pathophysiology, diagnosis and treatment, together with unpublished and new findings from young researchers. Basic scientists and clinicians are thereby involved in an exchange of information which will lead to new directions for future research and clinical management of inflammatory bowel diseases.
42 pages matching susceptibility in this book
Results 1-3 of 42
What people are saying - Write a review
We haven't found any reviews in the usual places.
GP Susceptibility genes for inflammatory bowel disease
lnterleukin1 3 gene polymorphisms as genetic markers
26 other sections not shown
6-mercaptopurine acid acute allele antibiotics antibody antigens apoptosis associated azathioprine bacteria cell lines chromosome chronic Clin Invest clinical colonic controlled trial Crohn's disease crypt cyclosporin cytokine dendritic cells dose drug effects epithelial cells erythrocyte experimental expression Falk Symposium Figure function Gastroenterol Gastroenterology gastrointestinal genes genetic growth factor IFN-y ileal Immunol increased induced inflammation inflammatory bowel disease inhibition interactions interleukin interleukin-10 intestinal epithelial cells intestinal inflammation intravenous ISBN Lactobacillus lamina propria linkage lymphocytes macrophages mediated mesalazine mice migration molecules murine myofibroblasts necrosis factor neutrophils NF-kB normal oral tolerance pathogenesis pathway patients with Crohn's patients with ulcerative peptides phenotype placebo Podolsky DK polymorphisms pouch pouchitis probiotic proinflammatory protein rats receptor refractory regulation remission response role small bowel steroids stimulation studies subgroups surgery susceptibility thalidomide therapeutic therapy TNF-a toxicity TPMT treatment trefoil tumor necrosis ulcerative colitis vitro